Literature DB >> 27875636

Evaluation of coronary artery disease in potential liver transplant recipients.

Brian J Hogan1, Enoka Gonsalkorala1, Michael A Heneghan1.   

Abstract

Improvements in the management of patients undergoing liver transplantation (LT) have resulted in a significant increase in survival in recent years. Cardiac disease is now the leading cause of early mortality, and the stress of major surgery, hemodynamic shifts, and the possibilities of hemorrhage or reperfusion syndrome require the recipient to have good baseline cardiac function. The prevalence of coronary artery disease (CAD) is increasing in LT candidates, especially in those with nonalcoholic fatty liver disease. In assessing LT recipients, we suggest a management paradigm of "quadruple assessment" to include (1) history, examination, and electrocardiogram; (2) transthoracic echocardiogram; (3) functional testing; and (4) where appropriate, direct assessment of CAD. The added value of functional testing, such as cardiopulmonary exercise testing, has been shown to be able to predict posttransplant complications independently of the presence of CV disease. This approach gives the assessment team the greatest chance of detecting and preventing complications related to CAD. Liver Transplantation 23 386-395 2017 AASLD.
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 27875636     DOI: 10.1002/lt.24679

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

Review 1.  CON: Noninvasive Imaging Is the Preferred Strategy for Cardiovascular Risk Stratification in This Patient.

Authors:  Shravan Dave; Abbey Barnard; Michel Mendler
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 2.  Preventive Strategies for Nonalcoholic Fatty Liver Disease After Liver Transplantation.

Authors:  Narendra S Choudhary; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2019-05-30

Review 3.  Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?

Authors:  Narendra S Choudhary; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-02-15

4.  Diagnostic accuracy of coronary computed tomography angiography-derived fractional flow reserve (CT-FFR) in patients before liver transplantation using CT-FFR machine learning algorithm.

Authors:  Maximilian Schuessler; Fuat Saner; Fadi Al-Rashid; Thomas Schlosser
Journal:  Eur Radiol       Date:  2022-06-22       Impact factor: 5.315

Review 5.  Optimizing patients with non-alcoholic fatty liver disease pre-transplant.

Authors:  Amine Benmassaoud; Marc Deschenes; Tianyan Chen; Peter Ghali; Giada Sebastiani
Journal:  Can Liver J       Date:  2020-08-20

6.  Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations.

Authors:  Lisa B VanWagner; Matthew E Harinstein; James R Runo; Christopher Darling; Marina Serper; Shelley Hall; Jon A Kobashigawa; Laura L Hammel
Journal:  Am J Transplant       Date:  2017-11-18       Impact factor: 8.086

Review 7.  Preoperative Evaluation of Coronary Artery Disease in Liver Transplant Candidates: Many Unanswered Questions in Clinical Practice.

Authors:  Maria Bonou; Sophie Mavrogeni; Chris J Kapelios; Marina Skouloudi; Constantina Aggeli; Evangelos Cholongitas; George Papatheodoridis; John Barbetseas
Journal:  Diagnostics (Basel)       Date:  2021-01-05

8.  Coronary artery bypass graft combined with liver transplantation in patients with advanced alcoholic liver cirrhosis: A case report.

Authors:  Junwu Chai; Kai Wang; Xiangrong Kong; Cheng Pan; Wentao Jiang; Wei Zhou; Honglei Chen; Fenlong Xue; Li Zhang; Zhongyang Shen
Journal:  Exp Ther Med       Date:  2020-03-11       Impact factor: 2.447

9.  Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study.

Authors:  William E Moody; Benjamin Holloway; Parthiban Arumugam; Sharon Gill; Yasmin S Wahid; Chris M Boivin; Louise E Thomson; Daniel S Berman; Matthew J Armstrong; James Ferguson; Richard P Steeds
Journal:  J Nucl Cardiol       Date:  2020-05-11       Impact factor: 5.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.